90196-84-2 Usage
Amine derivative
The compound is a derivative of an amine, which is a class of organic compounds that contains a nitrogen atom bonded to a hydrogen atom and an alkyl or aryl group.
Pyridine ring
The compound contains a pyridine ring, which is a six-membered aromatic ring that is similar in structure to benzene but contains a nitrogen atom in the ring.
Substitution at the 6-position
The pyridine ring in 2-(6-methylpyridin-3-yl)ethanamine is substituted with a methyl group (a CH3 group) at the 6-position, which means that the methyl group is attached to the 6th carbon atom of the pyridine ring.
Building block in organic synthesis
2-(6-methylpyridin-3-yl)ethanamine can be used as a building block in the synthesis of more complex organic compounds, such as pharmaceuticals, agrochemicals, and other fine chemicals.
Potential applications in medicinal chemistry and drug discovery
The compound may have potential applications in the field of medicinal chemistry and drug discovery, as it can be used as a starting material for the synthesis of compounds with potential biological activity.
Safety precautions
2-(6-methylpyridin-3-yl)ethanamine should be handled and used with proper safety precautions, such as wearing appropriate personal protective equipment and following good laboratory practices, to prevent exposure and potential adverse effects.
Check Digit Verification of cas no
The CAS Registry Mumber 90196-84-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,1,9 and 6 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 90196-84:
(7*9)+(6*0)+(5*1)+(4*9)+(3*6)+(2*8)+(1*4)=142
142 % 10 = 2
So 90196-84-2 is a valid CAS Registry Number.
90196-84-2Relevant academic research and scientific papers
2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL
-
Paragraph 0625, (2017/07/14)
Compounds of formula (VIII) and compositions for treating disorders related to TRPA1 are described herein.
